

## Immunisation news

### HPV vaccination success continues

Preliminary uptake data for HPV vaccinations given in the year up to June 2011 have recently been published ([see web link 1](#)). These figures show that uptake in the routine cohort of 12-13-year-old girls for first, second and third doses exceeds that for the same month in the previous two academic years (see table). Well done everyone, for achieving such impressive results so far.

#### HPV vaccine uptake in the routine cohort of girls aged 12-13 years by the end of June over three academic years

Dose (%)	Year	2008/09	2009/10	2010/11
First dose uptake		87.1	83.1	<b>87.4</b>
Second dose uptake		84.2	80.0	<b>85.5</b>
Third dose uptake		70.4	67.6	<b>76.6</b>

The annual data collection will take place in September 2011. This collection will also ask for updated figures from PCTs on girls vaccinated up until the age of 18 years. Guidance can be found at [web link 2](#).

At the start of the vaccination programme in September 2010, we wrote to all those involved in HPV vaccination to remind them to continue their efforts to identify and offer the vaccine to all females aged from 12 up to 18 years ([see web link 3](#)). This advice also applies to those girls and young women who may have missed the opportunity to be vaccinated at a younger age. Thank you for your continued efforts to protect this group against the risk of cervical cancer.

### Adolescent vaccinations – JCVI sub-committee call for evidence

The Joint Committee on Vaccination and Immunisation (JCVI) sub-committee on adolescent vaccinations will be considering over 2011 and 2012 a number of issues relating to vaccinations of young people aged 11-18 years.

To inform its considerations, the sub-committee welcomes submissions from interested parties of good quality scientific, medical, or economic evidence relevant to the issues under consideration. Submissions should reference peer-reviewed published material wherever possible.

For further information, including the issues under consideration, the data required and where to submit data, [see web link 4](#). Submissions should be sent **no later than 30 September 2011**.

## Pneumococcal vaccination programme to continue for those aged 65 and over

The Joint Committee on Vaccination and Immunisation (JCVI) has advised that the routine pneumococcal vaccination programme for people aged 65 and over should continue ([see web link 5](#)). The advice comes after a review of new analyses on the clinical effectiveness of pneumococcal polysaccharide vaccine (PPV) in older people. JCVI concluded that, whilst uncertainty remains about the effectiveness of PPV, there is better evidence from the UK experience of the vaccine suggesting that it provides some moderate short-term protection to those aged 65 years and older, although protection may be less and wane faster in older age groups and for some clinical risk groups. Furthermore, the findings suggest that the programme remains cost effective, despite the limited effectiveness of the vaccine.

DH has accepted JCVI's advice ([see web link 6](#)). Therefore, the routine pneumococcal vaccination programme for those aged 65 years and older is continuing and clinicians should continue to follow the existing guidance on the use of PPV in the pneumococcal chapter of the Green Book ([see web link 7](#)).

## Healthcare worker influenza vaccine uptake survey 2011/12

An article in the April 2011 edition of *Vaccine Update* provided clarification on the responsibility for providing the central return of mandatory vaccine coverage data for a number of collections following the separation of commissioning and provision of services within PCTs, and the formation of PCT clusters ([see web link 8](#)).

The Department has received a number of enquiries regarding responsibility for the central return of data on the uptake of the trivalent seasonal influenza vaccine in frontline healthcare workers during the 2011/12 influenza season, approval for which is being sought from the Review of Central Returns (ROCR). The Department would like to clarify that all trusts, including primary care, acute, mental health, ambulance, care and foundation trusts are responsible for submission of data on the seasonal influenza vaccination of frontline healthcare workers, including all those in healthcare providing organisations from which they commission services (should ROCR approve the collection).

It remains the responsibility of commissioners to ensure that these data are submitted and complete. This guidance supplements information in Annex D of the professional letter on the Seasonal influenza vaccination programme for 2011/12 from the Chief Medical Officer of 25 May 2011 ([see web link 9](#)). A user guide for data providers will be issued closer to the start of the vaccination programme.

## Change to information on ovalbumin-content of influenza vaccines

Following publication of the revised Green Book chapter on influenza earlier this year, it has come to our attention that some of the information provided on the influenza vaccines available for the 2011/12 season was in error. We have now contacted each manufacturer to obtain the latest information and a revised influenza Green Book chapter has now been published at [web link 7](#). A revised table, setting out the trivalent seasonal influenza vaccines available for the 2011/12 season, with the revised information highlighted, is attached below.

Please ensure that you refer to the table provided in the influenza chapter of the Green Book for the ovalbumin-content of seasonal influenza vaccines, and not the CMO letter published on 25 May 2011.

Supplier	Name of product	Vaccine type	Age indications	Ovalbumin content per 0.5ml dose	Contact details
Abbott Healthcare	Influvac®	Surface antigen, inactivated	From 6 months	No more than 0.1µg	0800 358 7468
Abbott Healthcare	Imuvac®	Surface antigen, inactivated	From 6 months	No more than 0.1µg	0800 358 7468
Baxter Healthcare	Preflucel®	Split virion, inactivated, prepared on Vero cells	From 18 years	No ovalbumin	01635 206 265
Crucell UK Ltd	Viroflu®	Surface antigen, inactivated	From 6 months	No more than 0.05µg	0844 800 3907
GlaxoSmithKline	Fluarix®	Split virion inactivated virus	From 6 months	No more than 0.05µg	0800 783 0470
MASTA	Imuvac®	Surface antigen, inactivated	From 6 months	No more than 0.1µg	0113 238 7500
Novartis Vaccines	Agrippal®	Surface antigen, inactivated	From 6 months	No more than 0.2µg	08457 451 500
Novartis Vaccines	Fluvirin®*	Surface antigen, inactivated	From 4 years	No more than 1µg	08457 451 500
Pfizer Vaccines	CSL Inactivated Influenza Vaccine	Split virion inactivated virus	From 5 years	No more than 1µg	0800 089 4033
Pfizer Vaccines	Enzira®	Split virion inactivated virus	From 5 years	No more than 1µg	0800 089 4033
Sanofi Pasteur MSD	Inactivated Influenza Vaccine (Split Virion) BP	Split virion inactivated virus	From 6 months	No more than 0.024µg	0800 085 5511
Sanofi Pasteur MSD	Intanza® 9µg	Split virion inactivated virus	From 18 – 59 years	No more than 0.024µg (0.1ml dose)	0800 085 5511
Sanofi Pasteur MSD	Intanza® 15µg	Split virion inactivated virus	From 60 years	No more than 0.024µg (0.1ml dose)	0800 085 5511

None of the influenza vaccines for the 2011/12 season contains thiomersal as an added preservative.

\*This vaccine states in its SPC that it contains traces of thiomersal that are left over from the manufacturing process.

## Restrictions placed on use of Pandemrix in children

On 21 July 2011, the European Medicines Agency (EMA) announced a restriction on the licence for Pandemrix H1N1 swine flu vaccine regarding use in children and adolescents ([see web link 10](#)). This followed a review of reports of narcolepsy in association with the vaccine, mainly in Sweden and Finland, during the pandemic. The licence now states that Pandemrix may only be used in persons aged under 20 years if seasonal trivalent vaccine is not available and if there is a particular need to immunise against H1N1. No restrictions on use in adults were imposed, and the overall balance of risks and benefits remains favourable.

The CMO letter on seasonal influenza vaccination for 2011/12 states that the seasonal trivalent vaccine is recommended to protect against influenza in the coming influenza season ([see web link 11](#)).

GPs should ensure that they have enough seasonal trivalent vaccine to vaccinate their patients who are most at risk of serious illness or death should they develop flu. At present, there is no plan to use Pandemrix for the 2011/12 flu season.

## Resources

### Green Book

Several chapters have been revised and uploaded recently, including the influenza chapter where the ovalbumin-content of some vaccines has been updated (see above and [web link 7](#)).

## Vaccine supply

### GSK temporarily stops production of Typherix and Hepatyrix vaccines

A delay in a new manufacturing facility coming on line at GSK has meant that capacity normally reserved for producing typhoid antigen has had to be switched to the production of critical childhood vaccines. This situation is expected to last until the end of 2013. Current stocks of Typherix are expected to last until the end of July, and Hepatyrix until the end of the year. GSK stresses that this break in supply has nothing to do with vaccine quality or safety issues. Alternative hep A vaccines are available from GSK, Sanofi Pasteur MSD or Crucell while typhoid vaccines are available from Sanofi Pasteur MSD or Crucell.

For more information please contact GSK's customer contact team on 0808 100 9997, Sanofi Pasteur MSD's customer service department on 0800 085 5511 or Crucell's customer services on 0844 800 3907.

## Bank Holiday Monday 29 August 2011 – vaccine ordering and delivery arrangements

Due to the August Bank holiday, there will be no deliveries on Monday 29 August. This holiday will impact on the Movianto UK delivery schedule as detailed in the table below.

Customers with a scheduled delivery day of Monday are reminded to be prepared for the break in delivery and to order accordingly. Please make sure you have sufficient room in your vaccine fridge.

Scheduled delivery day	Order cut off day (orders to be placed by noon)	Revised delivery day (where applicable)
Monday 22 August	Thursday 18 August	n/a
Tuesday 23 August	Friday 19 August	n/a
Wednesday 24 August	Monday 22 August	n/a
Thursday 25 August	Tuesday 23 August	n/a
Friday 26 August	Wednesday 24 August	n/a
Monday 29 August	No deliveries	Monday 5 September
Tuesday 30 August	Thursday 25 August	n/a
Wednesday 31 August	Friday 26 August	n/a
Thursday 1 September	Tuesday 30 August	n/a
Friday 2 September	Wednesday 31 August	n/a

## Web links

- Web link 1** [www.dh.gov.uk/en/Publichealth/Immunisation/Keyvaccineinformation/DH\\_104010#\\_2](http://www.dh.gov.uk/en/Publichealth/Immunisation/Keyvaccineinformation/DH_104010#_2)
- Web link 2** [www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH\\_128689](http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_128689)
- Web link 3** [http://www.dh.gov.uk/en/Publicationsandstatistics/Lettersandcirculars/Dearcolleagueletters/DH\\_119498](http://www.dh.gov.uk/en/Publicationsandstatistics/Lettersandcirculars/Dearcolleagueletters/DH_119498)
- Web link 4** [www.dh.gov.uk/ab/JCVI](http://www.dh.gov.uk/ab/JCVI)
- Web link 5** [www.dh.gov.uk/ab/JCVI/DH\\_094744](http://www.dh.gov.uk/ab/JCVI/DH_094744)
- Web link 6** [www.dh.gov.uk/en/Publicationsandstatistics/Lettersandcirculars/Dearcolleagueletters/DH\\_128535](http://www.dh.gov.uk/en/Publicationsandstatistics/Lettersandcirculars/Dearcolleagueletters/DH_128535)
- Web link 7** [www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH\\_079917](http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_079917)
- Web link 8** [www.dh.gov.uk/en/Publichealth/Immunisation/Vaccineupdate/index.htm](http://www.dh.gov.uk/en/Publichealth/Immunisation/Vaccineupdate/index.htm)
- Web link 9** [www.dh.gov.uk/en/Publicationsandstatistics/Lettersandcirculars/Professionalletters/Chiefmedicalofficerletters/DH\\_127048](http://www.dh.gov.uk/en/Publicationsandstatistics/Lettersandcirculars/Professionalletters/Chiefmedicalofficerletters/DH_127048)
- Web link 10** [www.ema.europa.eu/docs/en\\_GB/document\\_library/Press\\_release/2011/07/WC500109182.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2011/07/WC500109182.pdf)
- Web link 11** [www.dh.gov.uk/prod\\_consum\\_dh/groups/dh\\_digitalassets/documents/digitalasset/dh\\_128175.pdf](http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_128175.pdf)

## Register now – feedback – contact us

To receive a copy of Vaccine Update emailed direct to you each month, to provide any comments or suggestions, or if you have a query about any aspect of vaccine supply, please email us at [vaccine.supply@dh.gsi.gov.uk](mailto:vaccine.supply@dh.gsi.gov.uk)

This document has been authorised by the Department of Health: Gateway reference no: 16428